Pamaquine
From Wikipedia, the free encyclopedia
 |
|
|
Pamaquine
|
|
| Systematic (IUPAC) name | |
| N,N-diethyl-N'-(6-methoxyquinolin-8-yl)pentane- 1,4-diamine |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C19H29N3O |
| Mol. mass | 315.453 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pamaquine is an 8-aminoquinoline drug used for the treatment of malaria. It is closely related to primaquine.
Contents |
[edit] History
Pamaquine was the first synthetic antimalarial drug.
[edit] Adverse effects
Like primaquine, pamaquine causes haemolytic anaemia in patients with G6PD deficiency. Patients should therefore always be screened for G6PD deficiency prior to being prescribed pamaquine.
[edit] Uses
Pamaquine is effective against the hypnozoites of the relapsing malarias (P. vivax and P. ovale); and unlike primaquine, it is also very effective against the erythrocytic stages of all four human malarias. One small clinical trial of pamaquine as a causal prophylactic was disappointing[1] (whereas primaquine is an extremely effective causal prophylactic).
[edit] Dosing
60 mg once daily for 14–21 days.
When treating Plasmodium vivax, an initial course of chloroquine is unnecessary.
[edit] Synonyms
- Plasmaquine
[edit] References
- ^ Sweeney AW, Blackburn CRB, KH Rieckmann. (2004). "Short report: The activity of pamaquine, an 8-aminoquinoline drug, against sporozoite-induced infections of Plasmodium vivax (New Guinea strains)". Am J Trop Med Hyg 71 (2): 187–189. PMID 15306708.
|
||||||||||||||||||||
